GLP-1 receptor agonists for type 2 diabetes.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. GLP-1 agonists and the gut microbiome: A bidirectional relationship.British journal of clinical pharmacology · 2026
   Review
2. Association of formulary restrictions and initiation of an SGLT2i or GLP1-RA among Medicare beneficiaries with type 2 diabetes.Diabetes research and clinical practice · 2022
   Article
3. Mechanism of Roux-en-Y gastric bypass treatment for type 2 diabetes in rats.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2013
   Article
4. Insulin resistance and chronic liver disease.World journal of hepatology · 2011
   Article

Corrections and comments

• Commented on by
  Adverse events in diabetes drug trial.2009
• Comment on
  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).2009

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as